HAVE YOU OR A LOVED ONE BEEN DIAGNOSED WITH CANCER FOLLOWING THE USE OF A MORCELLATOR DURING SURGERY?

 

The nationally recognized pharmaceutical device firm of Holland Groves is currently reviewing cases on behalf of women who have been diagnosed with cancer following the use of a morcellator during a hysterectomy or uterine fibroid removal.  The risks associated with the use of morcellators are now recognized throughout the medical community and a number of leading physicians and hospitals have halted the use of the device.

 

Morcellators allow doctors to cut uterine fibroids, or even the uterus itself, via a bladed tube, and the tissue can then be removed through a smaller incision in the abdomen.  These morcellators leave behind tiny tissue and pose an unreasonable risk of causing the spread of an aggressive cancer throughout the abdomen and pelvis.  The manufacturers of these devices include Ethicon, Blue Endo, Karl Storz, Olympus, FemRx, Hologic, Lumenis, Inc., Interlace Medical, Smith & Nephew, Nouvag, LiNA Medical, and Richard Wolf.

 

In April 2014, the FDA issued the following warning:

 

      When used for a hysterectomy or myomectomy in women with uterine fibroids, laparoscopic power morcellation poses a risk of spreading unsuspected cancerous tissue, notably uterine sarcomas, beyond the uterus.  Health care providers and patients should carefully consider available alternative treatment options for symptomatic uterine fibroids.  Based on currently available information, the FDA discourages the use of laparoscopic power morcellation during hysterectomy or myomectomy for uterine fibroids.

 

      If laparoscopic power morcellation is performed in women with unsuspected uterine sarcoma, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival.  For this reason, and because there is no reliable method for predicting whether a woman with fibroids may have a uterine sarcoma, the FDA discourages the use of laparoscopic power morcellation during hysterectomy or myomectomy for uterine fibroids.


UPDATE: 7/30/14 JOHNSON AND JOHNSON (OWNER OF ETHICON) PULLS MORCELLATOR FROM MARKET 

If you or a loved one have been diagnosed with cancer following the use of a morcellator, including those listed below, please complete the information below for a free consultation to determine if you are entitled to compensation.

 

  • Leiomyosarcoma (LMS)
  • Uterine cancer
  • Myelosarcoma
  • Uterine Sarcoma